A pharma company developing a first-in-class therapeutic to treat rare paediatric neurodegenerative disorders was nearing NDA approval in multiple indications and was ready to initiate fund raising activities to support its next steps. Alacrita had previously been commissioned by an investor to conduct due diligence on the company for an earlier funding round. This time, we were approached directly by the pharma company to perform an updated due diligence exercise and develop an independent report of the company’s progress for other potential investors.
Our neurology expert reviewed all of the available clinical data for the company’s lead product and developed an opinion on the strength of the data and the likelihood of approval in each indication. Using these outputs, our market analysis expert quantified the commercial potential in each indication. We presented our findings to the pharma company, which subsequently used the output of the due diligence to engage with potential investors.